Prosecution Insights
Last updated: November 12, 2026

Wave Life Sciences Ltd.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days

Analysis

Wave Life Sciences Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters span 4 distinct examiners and 3 distinct art units, showing separate examiner assignments alongside some art-unit overlap.

MOORE, JOHN DAVID is the busiest examiner, with 1 pending action. Since the pending matters are not concentrated with one examiner, prosecution planning should preserve matter-level tracking across the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (75%)
1
Medium (25%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (25%)
Double-patenting + other1 (25%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MOORE, JOHN DAVID 1 61.1% +28.3%
CESARE, JOSEPH DAVID 1 0.0% +0.0%
WILSON, MICHAEL C 1 41.5% +17.8%
VANHORN, ABIGAIL LOUISE 1 46.7% +22.8%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18174127 IMMUNOASSAYS FOR DETECTING WILD TYPE HUNTINGTIN PROTEIN AND METHODS OF TREATMENT EMPLOYING SUCH IMMUNOASSAYS CESARE, JOSEPH DAVID 70d overdue
18022509 CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF WILSON, MICHAEL C 8d overdue
18695348 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MOORE, JOHN DAVID —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18022509 CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF WILSON, MICHAEL C 8d overdue
18695348 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MOORE, JOHN DAVID —
17926967 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO VANHORN, ABIGAIL LOUISE —

Top Art Units

Art UnitApps
1638 2
1675 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18695348 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MOORE, JOHN DAVID 1638 §102§103§112 Non-Final OA — Pending Mar 25, 2024
18174127 IMMUNOASSAYS FOR DETECTING WILD TYPE HUNTINGTIN PROTEIN AND METHODS OF TREATMENT EMPLOYING SUCH IMMUNOASSAYS CESARE, JOSEPH DAVID 1675 §101§103§112 Final Rejection 70d overdue Pending Feb 24, 2023
18022509 CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF WILSON, MICHAEL C 1638 §103§112 Final Rejection 8d overdue Pending Feb 21, 2023
17926967 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO VANHORN, ABIGAIL LOUISE 1636 §103§112DP Non-Final OA — Pending Nov 21, 2022

Managing Wave Life Sciences Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Wave Life Sciences Ltd. have?

Wave Life Sciences Ltd. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.

Which USPTO examiner handles the most Wave Life Sciences Ltd. applications?

John David Moore has the most, with 1 of Wave Life Sciences Ltd.'s pending office actions.

What technology area are Wave Life Sciences Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month